The Differences Between the Vaccines Matter

The Atlantic, March 7, 2021: Public-health officials are enthusiastic about all 3 COVID-19 vaccines available in the U.S. For example, Virginia’s vaccine coordinator stated, “A hundred percent efficacy against deaths and hospitalizations? That’s all I need to hear.” But experts, including NCHR, point out that there were too few people with severe COVID in the vaccine studies to draw conclusions.

Read More »

Drug Industry Pushes FDA to Solve Growing Inspection Backlog

Politico, March 2, 2021: The FDA is under pressure from the pharmaceutical industry to address the growing backlog of drug inspections — nearly a year after Covid-19 prompted the agency to halt most plant visits. From March through September, FDA inspected just three plants outside the U.S. and 52 within the U.S., well below the 600 and 400, respectively in each of the prior two years. NCHR president reports device inspections have also dropped dramatically

Read More »